PGP and cancer: Starting from the 1990s, three taxanes have been employed in the treatment of various cancers: paclitaxel (PTX), which was approved for medical use as Taxol® in 1993; docetaxel, a synthetic derivative of PTX [104] that entered the market in 1995 under the brand name Taxotere®; and the semi-synthetic cabazitaxel [103], marketed since 2010 under the trade name Jevtana®, which was demonstrated to be superior to PTX and docetaxel, due to the reduced affinity for the multidrug-resistant P-glycoprotein (P-gp) [105].